The approval covers adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received ALK inhibitors.

USA—The US Food and Drug Administration (FDA) has granted accelerated approval to GSK’s Nelkarmi (neladalkib) for advanced lung cancer, expanding the British pharmaceutical company’s oncology portfolio following its US$10.6 billion acquisition of Nuvalent in July 2026.
The approval covers adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received ALK inhibitors.
These include Roche’s Alecensa (alectinib), one of the established treatments for this form of lung cancer.
Clinical evidence and treatment potential
The FDA based its decision on results from the Phase I/II ALKOVE-1 trial (NCT05384626).
Among patients previously treated with Alecensa, Nelkarmi achieved a confirmed overall response rate (ORR) of 49%.
More than half of these responses lasted at least 12 months, indicating its potential to address disease progression following earlier ALK-targeted treatment.
GSK Chief Scientific Officer Tony Wood said the medicine was designed to address key challenges in ALK-positive NSCLC through its activity against a broad range of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity.
He noted that patients with ALK-positive lung cancer are often younger and may require treatment over several years, making effective and tolerable therapies important.
The approval gives eligible patients in the US access to another targeted treatment option.
Nuvalent acquisition expands GSK’s oncology portfolio
Before 2026, GSK had not secured US approval for a medicine specifically targeting lung cancer.
The Nuvalent acquisition has changed this, delivering two oncology approvals within a short period.
The first came in July 2026, when the FDA approved Jideytro (zidesamtinib) for patients with previously treated ROS1-positive NSCLC.
The medicine became the first product from Nuvalent’s portfolio to reach the US market following the acquisition.
Although both medicines strengthen GSK’s position in targeted lung cancer treatment, Nelkarmi could generate higher sales because ALK-positive NSCLC represents a larger commercial opportunity than ROS1-positive disease.
GlobalData’s Pharma Intelligence Centre forecasts that Nelkarmi will generate US$1.2billion in sales by 2032, compared with US$830million for Jideytro.
However, Roche’s Alecensa remains a significant competitor, having generated US$1.85 billion in revenue in 2025.
First-line treatment remains a key commercial opportunity
Despite the latest approval, expanding Nelkarmi into the first-line treatment setting remains an important opportunity for GSK.
Citi analysts identified this as a key driver of the medicine’s long-term commercial potential.
Any expansion of the current indication will depend on results from the ongoing Phase III ALKAZAR study (NCT06765109), which is evaluating Nelkarmi in patients who have not previously received tyrosine kinase inhibitors (TKIs).
Be the first to leave a comment